Literature DB >> 13129701

Promising developments bringing prion diseases closer to therapy and prophylaxis.

Sabine Gilch1, Hermann M Schätzl.   

Abstract

Prion diseases are fatal, infectious, neurodegenerative disorders, and there are no available therapeutic or prophylactic regimens. The potential of immune system components in combating peripheral prion infection has long been underestimated, but recent studies have suggested that such molecules could be effective. For example, promising results have been reported from a passive vaccination study in prion-infected mice. In addition, elegant transgenic mouse studies have shown the inhibitory effect on prion propagation of a soluble immunoglobulin G (IgG)-like dimeric prion protein. This type of molecule might represent a new class of anti-prion compounds.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13129701     DOI: 10.1016/s1471-4914(03)00144-8

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  3 in total

1.  In vitro neutralization of prions with PrP(Sc)-specific antibodies.

Authors:  Ryan Taschuk; Jacques Van der Merwe; Kristen Marciniuk; Andrew Potter; Neil Cashman; Philip Griebel; Scott Napper
Journal:  Prion       Date:  2015       Impact factor: 3.931

2.  Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells.

Authors:  Alessandra Handisurya; Sabine Gilch; Dorian Winter; Saeed Shafti-Keramat; Dieter Maurer; Hermann M Schätzl; Reinhard Kirnbauer
Journal:  FEBS J       Date:  2007-02-20       Impact factor: 5.542

3.  The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions.

Authors:  Basant A Abdulrahman; Dalia Abdelaziz; Simrika Thapa; Li Lu; Shubha Jain; Sabine Gilch; Stefan Proniuk; Alexander Zukiwski; Hermann M Schatzl
Journal:  Sci Rep       Date:  2017-12-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.